Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.63
−$0.02 · -1.21%
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., a research and development partnership with The University of Texas MD Anderson Cancer Center, and both a patent licensing and R&D agreement with the National Cancer Institute. Previously known as ZIOPHARM Oncology, Inc., the company adopted its current name, Alaunos Therapeutics, Inc., in January 2022. Its headquarters are located in Houston, Texas.
Previous close
$1.63
−$0.02 · -1.21%
Regular session · ET · Market data may be delayed.
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., a research and development partnership with The University of Texas MD Anderson Cancer Center, and both a patent licensing and R&D agreement with the National Cancer Institute. Previously known as ZIOPHARM Oncology, Inc., the company adopted its current name, Alaunos Therapeutics, Inc., in January 2022. Its headquarters are located in Houston, Texas.
Day range
Current $1.63
52-week range
Current $1.63
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
2
Overpriced
Sentiment
60
Mixed
Risk
69
High Risk
Momentum
21
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., a research and development partnership with The University of Texas MD Anderson Cancer Center, and both a patent licensing and R&D agreement with the National Cancer Institute. Previously known as ZIOPHARM Oncology, Inc., the company adopted its current name, Alaunos Therapeutics, Inc., in January 2022. Its headquarters are located in Houston, Texas.
Day range
Current $1.63
52-week range
Current $1.63
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 5K USD | 10K USD | 5K USD | 2.92M USD | 398K USD |
| Cost of goods sold | 1.36M USD | 362K USD | 4.8M USD | 22.52M USD | 47.28M USD |
| Gross profit | −1.36M USD | −352K USD | −4.8M USD | −19.6M USD | −46.88M USD |
| Research and development | 1.36M USD | 362K USD | 16.28M USD | 25.02M USD | 49.64M USD |
| Selling, general, and administrative | 2.87M USD | 4.46M USD | 12.22M USD | 13.14M USD | 26.28M USD |
| Operating expenses | 2.87M USD | 4.46M USD | 29.47M USD | 15.51M USD | 30.67M USD |
| Interest expense | — | — | 1.92M USD | 3.15M USD | 1.19M USD |
| Depreciation and amortization | 7K USD | 2K USD | 2.32M USD | 2.76M USD | 2.6M USD |
| Operating income | −4.23M USD | −4.81M USD | −34.27M USD | −35.11M USD | −77.55M USD |
| Net income | −4.18M USD | −4.68M USD | −35.14M USD | −37.73M USD | −78.75M USD |
Company facts updated Sep 7, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 18, 2024 | 1:10 | — | — |
Stock split | Feb 1, 2024 | 1:15 | — | — |
Stock split | Aug 24, 2005 | 1:40 | — | — |
Effective Jul 18, 2024
1:10
Effective Feb 1, 2024
1:15
Effective Aug 24, 2005
1:40
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
